# Monte Rosa Therapeutics, Inc.: overview GLUE · Nasdaq · CIK 1826457 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/glue.md) · [Financials](/companies/glue/financials.md) · [Filings](/companies/glue/filings.md) · [Insiders](/companies/glue/insiders.md) Latest reported revenue: [$9.0m](/filings/0001193125-26-336711.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, accession 0001193125-26-336711). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [9.2](/filings/0001193125-25-268045.md) | [60.6 d](/filings/0001193125-26-109360.md) | [84.9](/filings/0001193125-26-210358.md) | [23.2](/filings/0001193125-26-336711.md) | [12.8](/filings/0001193125-25-268045.md) | [2.8 d](/filings/0001193125-26-109360.md) | [4.2](/filings/0001193125-26-210358.md) | [9.0](/filings/0001193125-26-336711.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(287.8%)](/filings/0001193125-25-268045.md) | [21.4% d](/filings/0001193125-26-109360.md) | [51.9%](/filings/0001193125-26-210358.md) | [(67.1%)](/filings/0001193125-26-336711.md) | [(258.3%)](/filings/0001193125-25-268045.md) | [(1787.7%) d](/filings/0001193125-26-109360.md) | [(1188.5%)](/filings/0001193125-26-210358.md) | [(547.8%)](/filings/0001193125-26-336711.md) | | Net margin | % | [(258.9%)](/filings/0001193125-25-268045.md) | [22.2% d](/filings/0001193125-26-109360.md) | [55.2%](/filings/0001193125-26-336711.md) | [(53.0%)](/filings/0001193125-26-336711.md) | [(212.1%)](/filings/0001193125-25-268045.md) | [(1658.0%) d](/filings/0001193125-26-336711.md) | [(1057.1%)](/filings/0001193125-26-336711.md) | [(483.9%)](/filings/0001193125-26-336711.md) | | Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Free cash flow | $m | [(21.4) d](/filings/0001193125-25-268045.md) | [129 d](/filings/0001193125-26-109360.md) | [(47.1)](/filings/0001193125-26-210358.md) | [(36.4) d](/filings/0001193125-26-336711.md) | [99.8 d](/filings/0001193125-25-268045.md) | [(43.8) d](/filings/0001193125-26-109360.md) | [(39.2)](/filings/0001193125-26-210358.md) | [(48.8) d](/filings/0001193125-26-336711.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL not reported. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | [0.0](/filings/0000950170-25-042344.md) | [75.6](/filings/0001193125-26-109360.md) | [124](/filings/0001193125-26-109360.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | [(107.3%)](/filings/0001193125-26-109360.md) | [(43.8%)](/filings/0001193125-26-109360.md) | | Net margin | % | not reported | not reported | not reported | [(96.1%)](/filings/0001193125-26-109360.md) | [(31.2%)](/filings/0001193125-26-336711.md) | | Diluted EPS | $ per share | [(2.96)](/filings/0000950170-22-004927.md) | not reported | not reported | not reported | not reported | | Free cash flow | $m | [(69.1)](/filings/0000950170-23-008440.md) | [(105)](/filings/0000950170-24-031150.md) | [(62.8)](/filings/0000950170-25-042344.md) | [38.0](/filings/0001193125-26-109360.md) | [(27.5)](/filings/0001193125-26-109360.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/glue/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [NEA Management Company, LLC](/funds/1512848.md) | 2026-06-30 | $186.2m | 7,692,298 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $165.6m | 6,843,087 | | Added +1,205,403 | | [TCG Crossover Management, LLC](/funds/1839948.md) | 2026-06-30 | $111.9m | 4,622,151 | | Unchanged | | [Vestal Point Capital, LP](/funds/1974915.md) | 2026-06-30 | $111.3m | 4,600,000 | | Added +996,535 | | [BVF INC/IL](/funds/1056807.md) | 2026-06-30 | $108.0m | 4,460,886 | | Unchanged | | [BAKER BROS. ADVISORS LP](/funds/1263508.md) | 2026-06-30 | $105.2m | 4,345,736 | | Unchanged | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $90.3m | 3,731,416 | | Added +377,436 | | [MONTANOVA CAPITAL, LLC](/funds/1569064.md) | 2026-06-30 | $85.9m | 3,549,539 | | Reduced −677,270 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $82.6m | 3,412,927 | | Added +312,682 | | [Versant Venture Management, LLC](/funds/1560009.md) | 2026-06-30 | $77.0m | 3,180,780 | | Unchanged | ## Recent filings [All 398 filings](/companies/glue/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-01 | 11:38 ET | [8-K](/filings/0001193125-26-409833.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-409833 | | 2026-09-08 | 11:02 ET | [8-K](/filings/0001193125-26-384360.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-384360 | | 2026-08-06 | 11:09 ET | [10-Q](/filings/0001193125-26-336711.md) | Quarterly report, period 2026-06-30 | 0001193125-26-336711 | | 2026-08-06 | 11:04 ET | [8-K](/filings/0001193125-26-336681.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-336681 | | 2026-07-06 | 21:51 ET | [SCHEDULE 13D/A](/filings/0001072613-26-000558.md) | Ownership report, active investor, amended | 0001072613-26-000558 | | 2026-06-11 | 20:01 ET | [8-K](/filings/0001193125-26-267465.md) | 5.07 Shareholder vote results | 0001193125-26-267465 | | 2026-05-07 | 11:30 ET | [10-Q](/filings/0001193125-26-210358.md) | Quarterly report, period 2026-03-31 | 0001193125-26-210358 | | 2026-05-07 | 11:05 ET | [8-K](/filings/0001193125-26-210298.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-210298 | | 2026-04-29 | 20:01 ET | [DEF 14A](/filings/0001193125-26-191439.md) | Proxy statement, period 2026-04-29 | 0001193125-26-191439 | | 2026-03-19 | 20:05 ET | [SCHEDULE 13D/A](/filings/0001072613-26-000294.md) | Ownership report, active investor, amended | 0001072613-26-000294 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-109360.md), filed Mar 17, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/d1f3e8da-8b8d-4d0f-854e-9fd4f6bfd8a1) ## About the filer - CIK: 1826457 - Tickers: GLUE - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.